Scope and Claims Analysis of US Patent 5,389,618 (Heterogeneous Sulfated Heparin Polysaccharide “Admixture” with Improved Bioavailability and Anti‑Xa Activity)

US Patent 5,389,618 claims a specific class of heterogeneous, intimate admixtures of sulfated heparinic polysaccharides (heparin-derived) defined primarily by molecular-weight distribution, physicochemical ratios, and functional performance (bioavailability/antithrombotic activity > heparin; anti‑Xa activity ~90–100 IU), with multiple dependent claim “filters” limiting dermatan sulfate content, endgroup structure (2‑O‑sulfo‑4‑enopyranosuronic endgroup), origin (porcine/bovine), and a process defined by benzethonium/long-chain quaternary ammonium salting, controlled partial esterification, and base depolymerization.

This patent’s enforceable scope is driven by (1) the composition definition in independent claim 1 and (2) the process definition in independent claim 7, with extensive downstream coverage in claims 23–32 for products and methods of prevention/treatment and compositions.

What exactly is claimed in US 5,389,618? (Composition scope, molecular-weight cutoffs, and functional performance)

Featured snippet answer: US 5,389,618 claims a heparin-derived heterogeneous sulfated polysaccharide admixture with a specific chain-length distribution (percent ranges across <2,000 Da / 2,000–8,000 Da / >8,000 Da), a molecular-weight ratio of Mw/Mn 1.3–1.6, an average molecular weight ~3,500–5,500 Da, <2% dermatan sulfate, specific endgroups, and improved bioavailability/antithrombotic activity over heparin, plus anti‑Xa activity around 90–100 IU.

Core independent composition claim structure (Claim 1)

Claim 1 defines the admixture as:

“Heterogeneous intimate admixture” of sulfated heparinic polysaccharides.
Molecular-weight distribution:
- 9% to 20% of chains with molecular weight < 2,000 Da
- 5% to 20% of chains with molecular weight > 8,000 Da
- 60% to 86% of chains with molecular weight between 2,000 and 8,000 Da
Polydispersity / ratio constraint:
- Mw/Mn = 1.3 to 1.6
Functional performance / property constraints:
- (i) bioavailability and antithrombotic activity greater than heparin
- (ii) average molecular weight between ~3,500 and 5,500 Da
Composition is further qualified as “consisting essentially of” in the preamble-to-body language of Claim 1, which narrows what additional components/impurities may be present while still allowing non-significant extras.

“Consisting essentially of” impacts on enforceability

Because Claim 1 states consisting essentially of (rather than open “comprising”), the scope is tighter around:

permissible impurities and non-target glycosaminoglycans, and
any additional polymer species that could change the performance or distribution.

Dependent claim 2 adds one explicit impurity limit: <2% dermatan sulfate, reinforcing that the “consisting essentially of” boundary likely matters in practice for other glycosaminoglycans.

Claim 31: process-qualified composition (composition made by the claimed process)

Claim 31 repeats essentially the same composition parameters as Claim 1 but adds that the admixture is “prepared by a process comprising” the steps of Claim 7 (salifying with long-chain quaternary ammonium salt, controlled esterification degree 9.5%–14%, depolymerization of that ester having degree of esterification 9.5%–14%).

This creates a composition claim that is additionally constrained by method of manufacture, which can be strategically important in product-by-process scenarios.

What do the dependent claims add to composition coverage? (Dermatan sulfate, endgroups, anti-Xa, and animal origin)

How is dermatan sulfate controlled? (Claim 2)

<2% dermatan sulfate in the admixture.

This directly limits competitor materials that are heparin-derived but with dermatan sulfate carryover.

What endgroup is required? (Claim 3)

Sulfated polysaccharides comprising a 2‑O‑sulfo‑4‑enopyranosuronic endgroup.

This narrows structural requirements beyond generic “heparin-like” sulfated polysaccharides and can limit design-around using alternative depolymerization routes that yield different terminal chemistries.

What anti‑Xa levels are specified? (Claims 4 and 28)

Claim 4: anti‑Xa activity about 90 IU
Claim 28: anti‑Xa activity about 100 IU

These are performance anchors. In infringement analysis, they can be used both as claim-matching requirements and as evidence of equivalence/non-equivalence if assays differ.

Which heparin origin does the claim cover? (Claims 5 and 6)

Porcine heparin origin (Claim 5)
Bovine heparin origin (Claim 6)

This is not a design-around opening; it is a tailoring limitation. A competitor starting from another origin (or using heparin not attributable to these sources) may avoid these dependents, though independent claim 1 may still capture the product if origin is not limited there.

How broad is the process claim in US 5,389,618? (Steps, reagents, and process parameters)

Featured snippet answer: Claim 7 covers a three-step chemical process: (a) salify heparin with a long-chain quaternary ammonium salt in aqueous medium, (b) esterify to 9.5%–14% degree of esterification using a chlorinated organic solvent system plus a chlorine compound (in dependent claims), and (c) depolymerize the ester using strong base in aqueous solution, with specific ratios and temperature/time constraints in further dependents.

Independent process claim (Claim 7)

Claim 7 includes:

(a) Salifying heparin with a long-chain quaternary ammonium salt in aqueous medium
(b) Esterifying the salt to a degree of esterification 9.5% to 14%
(c) Depolymerizing the ester having degree of esterification 9.5% to 14%

This defines a controlled chemistry sequence where:

the salt forms an intermediate suitable for partial esterification, and
the esterification degree is matched again for depolymerization.

What reagents and solvent system are specifically claimed? (Claims 8–11)

Claim 8: esterification (b) in chlorinated organic solvent in presence of a chlorine compound
Claim 9:
- chlorinated solvent: chloroform or methylene chloride
- chlorine compound: benzyl chloride
Claim 10:
- mixing about 1 part by weight heparin salt with about 1 part by volume benzyl chloride
- in 3 to 5 parts by volume chlorinated organic solvent
- temperature 25°C to 45°C
Claim 11: temperature 30°C to 40°C

This set is quite specific and gives strong leverage for process-based enforcement when an accused manufacturer uses the same chemistry and parameter bands.

What base and aqueous conditions are required? (Claims 12–17)

Claim 12: depolymerization treats the ester with strong base in aqueous solution
Claim 13: strong base to ester weight ratio 0.05 to 0.2
Claim 14: ratio 0.08 to 0.15
Claim 15: water to ester weight ratio 15 to 30
Claims 16–17: depolymerization temperature and time
- Claim 16: 50°C to 70°C, time 30 minutes to 3 hours
- Claim 17: 55°C to 65°C, time 1 to 2 hours

These parameters constrain process similarity. A competitor could attempt to move outside these windows, though that risks changing the resulting molecular-weight distribution and Mw/Mn ratio, which are already constrained in the product claims.

Alternative quaternary ammonium salt (Claims 18–19)

Claim 18: salifying with a benzethonium salt
Claim 19: benzethonium salt comprises benzethonium chloride

This provides a second explicit salification embodiment.

Partial ester identity qualifiers (Claims 20–21)

Claim 20: partial ester in step (b) comprising an aromatic ester
Claim 21: partial ester in step (b) comprising a sodium salt

These can tie process intermediates to product structure and may affect infringement arguments if an accused process uses a different cation/ester type.

Starting heparin preparation qualifier (Claim 22)

starting heparin precipitated from an alcohol

This can be a narrower constraint, but it also creates evidence hooks for sourcing and upstream processing.

How do claims 23–32 expand the patent to products and medical use? (Therapeutic composition and method claims)

Process-to-product: claim 23

Claim 23: heterogeneous intimate admixture “produced by the process” of Claim 7.

This is another product-by-process bridge.

Prophylaxis methods (Claims 24–26)

Claim 24: method for prevention of thrombotic episodes in humans
Claim 25: prevention of venous thromboses in postoperative humans
Claim 26: prevention in humans at risk of myocardial infarction

These are method-of-use claims. In practice, they attach infringement to administration of the claimed admixture to qualifying patient populations for the indicated prevention purposes.

Therapeutic compositions (Claims 27 and 30)

Claim 27: composition of matter for prevention including the admixture plus therapeutically acceptable carrier/diluent
Claim 30: composition of matter for treatment similarly structured

This covers many formulation styles (liquid/solid carriers) as long as the admixture meets the claimed parameters.

Treatment methods (Claims 29–30)

Claim 29: treatment of thrombotic episodes by administering the admixture
Claim 30: composition for treatment

Additional performance anchor (Claim 28)

Claim 28 repeats the admixture definition and tightens with anti‑Xa ~100 IU, giving another dependent path for infringement.

Patent landscape: what other patents likely intersect with US 5,389,618? (How to map claim scope vs. generic/biosimilar alternatives)

US 5,389,618 is not a biologic patent; it covers chemically defined heparin-derived polysaccharide compositions and a specific depolymerization/salt-ester route. In a litigation or FTO map, relevant intersection risks typically come from:

heparin depolymerization technologies that produce defined low/intermediate/high molecular weight fractions, with comparable Mw/Mn bands; and
method-of-use and formulation patents that do not require the same molecular distribution but still claim thromboembolism prevention/treatment by giving “heparin-like” products;
heparin-derived hemostatic/antithrombotic product families with performance benchmarks in anti‑Xa IU ranges.

Without a full corpus search of assignees, continuations, and corresponding filings, the only actionable landscape conclusions that can be made strictly from the claim text provided are internal:

The patent’s strongest claim set is the process-to-product linkage (Claims 7, 23, 31) and the composition definition (Claim 1).
Design-around can be attempted either by:
- altering the molecular-weight distribution percentages, Mw/Mn ratio, or average molecular weight; or
- altering impurity profile (dermatan sulfate), endgroup structure, anti‑Xa performance, or origin; or
- using a materially different manufacturing route such that the resulting admixture fails Claim 1 and Claim 31 simultaneously.
Litigation posture typically targets whether a competitor’s product matches Claim 1’s quantitative distribution metrics and performance predicates.

Given your prompt requests detailed scope/claims for US 5,389,618, the decisive “landscape” inference is that the patent sets a high-precision target product specification and a chemically constrained manufacturing route. That combination tends to raise evidence requirements for both sides:

plaintiffs need analytical data (SEC/MALS/GPC, Mn/Mw, fractionation, anti‑Xa assays, impurity profiling); and
defendants need manufacturing records and analytical comparisons to show non-meeting distribution/performance criteria.

Claim-by-claim infringement “coverage grid” (what you would compare in a product dossier or discovery)

Claim	Coverage type	Key technical fenceposts	Design-around levers
1	Composition	Chain distribution (%<2k, %2k–8k, %>8k), Mw/Mn 1.3–1.6, average MW ~3.5k–5.5k, bioavailability and antithrombotic activity > heparin, “consisting essentially of”	Shift fraction percentages or Mw/Mn band; change average MW; remove/alter terminal endgroups; change functional performance vs heparin benchmark
2	Dependent	Dermatan sulfate <2%	Use starting material with different impurity profile; change purification
3	Dependent	2‑O‑sulfo‑4‑enopyranosuronic endgroup	Use alternative depolymerization route/endgroup preservation
4	Dependent	anti‑Xa ~90 IU	Produce product with anti‑Xa outside that level (assay-dependent)
5–6	Dependent	Porcine vs bovine origin	Use different origin or demonstrate non-attributable source
7	Process	Quaternary ammonium salt salification, partial esterification degree 9.5–14, depolymerization of that ester with same degree	Change salt type, esterification chemistry, or depolymerization mechanism/parameters to exit those ranges
8–11	Dependent process	Chlorinated solvent: chloroform/methylene chloride; chlorine comp: benzyl chloride; temp 25–45 then 30–40; specific reagent volume ratios	Different solvent/chlorinating agent; different temperature/ratios
12–17	Dependent process	Strong base aqueous; base:ester 0.05–0.2 then 0.08–0.15; water:ester 15–30; temp 50–70 then 55–65; time windows	Change base ratios, water ratio, time, or temperature; use different base or non-aqueous route
18–19	Dependent process	benzethonium chloride	Use other quaternary ammonium salt
20–21	Dependent process	aromatic ester; sodium salt	Use non-aromatic ester/cation
22	Dependent	heparin precipitated from alcohol	Use different heparin prep route
23	Product-by-process	product “produced by” process of claim 7	Manufacture with different process
24–26	Method-of-use	prevention of thrombotic episodes; venous thrombosis postoperative; MI risk	Use non-claimed admixture; change dosing regimen or indication (note: claim text is focused on prevention scenarios)
27, 30	Formulation	admixture + acceptable carrier	Use different admixture or formulations where admixture fails Claim 1/31
28	Dependent composition	anti‑Xa ~100 IU	Produce anti‑Xa outside target
29–30	Treatment	treatment of thrombotic episodes	Avoid Claim 1/31 admixture

Key takeaways

US 5,389,618 is built around a tightly defined molecular-weight distribution and Mw/Mn ratio for heparin-derived sulfated polysaccharide admixtures, anchored to an average MW of ~3,500–5,500 Da and functional performance vs heparin.
The enforceable product scope is strongest where a competitor’s material matches Claim 1’s quantitative distribution and performance predicates, and also in process-qualified claims (Claims 7, 23, 31).
Dependent claims materially narrow product content with <2% dermatan sulfate and specific terminal chemistry (2‑O‑sulfo‑4‑enopyranosuronic endgroup), and they add performance anchors (anti‑Xa ~90–100 IU).
The manufacturing claims are chemically specific, tying infringement exposure to a quaternary ammonium salt salification, esterification at 9.5–14%, and base depolymerization with defined solvent, chlorine source, temperature, time, and reagent ratios in dependents.
Method-of-use and formulation claims extend protection to prevention and treatment of thrombotic episodes and postoperative venous thrombosis / MI risk prevention, provided the administered composition matches the claimed admixture.

FAQs

1) What part of US 5,389,618 is most difficult for a generic or follow-on manufacturer to avoid?
The quantitative product fences in Claim 1 (fraction percentages, Mw/Mn 1.3–1.6, and average MW ~3,500–5,500 Da) plus the “bioavailability and antithrombotic activity greater than heparin” predicate.

2) Can a competitor avoid infringement by changing only the anti‑Xa IU target?
Claim 1 does not specify anti‑Xa IU; anti‑Xa appears in dependents (Claims 4 and 28). Avoiding dependents may not avoid Claim 1 if Claim 1’s performance predicate still matches.

3) What is the role of the 2‑O‑sulfo‑4‑enopyranosuronic endgroup limitation?
It is a dependent structural requirement (Claim 3) that can be used to argue non-infringement if an accused product’s terminal chemistry is different even when other molecular-weight parameters match.

4) Does US 5,389,618 cover compositions as well as manufacturing methods?
Yes. It includes composition-of-matter claims (Claims 27 and 30) and product-by-process claims (Claims 23 and 31) in addition to process claims (Claim 7) and method-of-use claims (Claims 24–26 and 29).

5) How would litigation typically assess whether a candidate product meets Claim 1?
By measuring chain-length distribution (fractionation), computing Mn and Mw to confirm Mw/Mn 1.3–1.6, verifying average MW ~3,500–5,500 Da, quantifying dermatan sulfate (<2% if Claim 2 is invoked), and testing bioavailability/antithrombotic activity relative to heparin and anti‑Xa IU if dependents are asserted.

References

US Patent 5,389,618. “Heterogeneous intimate admixture of sulfated heparinic polysaccharides…” (claims provided in prompt).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	90 08013	Jun 26, 1990

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	398976	⤷ Start Trial
Austria	A128191	⤷ Start Trial
Australia	643531	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,389,618

Summary for Patent: 5,389,618